Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1945 1
1946 3
1947 3
1948 4
1949 3
1950 2
1951 3
1953 1
1954 2
1957 1
1958 1
1960 5
1962 2
1963 6
1964 3
1965 8
1966 9
1967 8
1968 7
1969 1
1970 6
1971 7
1972 12
1973 9
1974 3
1975 8
1976 10
1977 3
1978 7
1979 5
1980 9
1981 8
1982 11
1983 13
1984 6
1985 11
1986 16
1987 7
1988 11
1989 18
1990 20
1991 23
1992 18
1993 19
1994 17
1995 13
1996 18
1997 15
1998 10
1999 16
2000 31
2001 32
2002 29
2003 34
2004 34
2005 58
2006 44
2007 54
2008 48
2009 55
2010 60
2011 66
2012 70
2013 74
2014 63
2015 99
2016 106
2017 101
2018 90
2019 75
2020 83
2021 93
2022 69
2023 62
2024 63
2025 64
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,936 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for kahn s
Search for Kahon S instead (1 results)
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. Among authors: kahn se. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D'Alessio D; SURPASS-CVOT investigators. Nicholls SJ, et al. Among authors: kahn se. Am Heart J. 2024 Jan;267:1-11. doi: 10.1016/j.ahj.2023.09.007. Epub 2023 Sep 25. Am Heart J. 2024. PMID: 37758044 Free article. Clinical Trial.
Pulmonary Embolism.
Kahn SR, de Wit K. Kahn SR, et al. N Engl J Med. 2022 Jul 7;387(1):45-57. doi: 10.1056/NEJMcp2116489. N Engl J Med. 2022. PMID: 35793208 Review. No abstract available.
Venous thromboembolism.
Khan F, Tritschler T, Kahn SR, Rodger MA. Khan F, et al. Among authors: kahn sr. Lancet. 2021 Jul 3;398(10294):64-77. doi: 10.1016/S0140-6736(20)32658-1. Epub 2021 May 10. Lancet. 2021. PMID: 33984268 Review.
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, Colhoun HM, Cercato C, Dicker D, Horn DB, Hovingh GK, Jeppesen OK, Kokkinos A, Lincoff AM, Meyhöfer SM, Oral TK, Plutzky J, van Beek AP, Wilding JPH, Kushner RF. Ryan DH, et al. Among authors: kahn se. Nat Med. 2024 Jul;30(7):2049-2057. doi: 10.1038/s41591-024-02996-7. Epub 2024 May 13. Nat Med. 2024. PMID: 38740993 Free PMC article. Clinical Trial.
Long-term treatment of venous thromboembolism.
Kearon C, Kahn SR. Kearon C, et al. Among authors: kahn sr. Blood. 2020 Jan 30;135(5):317-325. doi: 10.1182/blood.2019002364. Blood. 2020. PMID: 31917402 Free article. Review.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Among authors: kahn se. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Rönnbäck C, Shah SJ, Verma S, Weeke PE, Lincoff AM; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Kosiborod MN, et al. Among authors: kahn se. Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30. Lancet. 2024. PMID: 39222642 Clinical Trial.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM. Colhoun HM, et al. Among authors: kahn se. Nat Med. 2024 Jul;30(7):2058-2066. doi: 10.1038/s41591-024-03015-5. Epub 2024 May 25. Nat Med. 2024. PMID: 38796653 Free PMC article. Clinical Trial.
1,936 results